TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03114397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation - active
Description: transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation - sham
Description: transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
Study: NCT03883451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helmet Model
Description: helmet model worn by football players
Study: NCT03354858

Intervention type: PROCEDURE
Intervention: Follicular flushing
Description: Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
Study: NCT02185144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH For Triples
Description: In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
Study: NCT00332098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused Treatment Plus Pharmacotherapy
Description: Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care Plus Pharmacotherapy
Description: Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
Study: NCT03178942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Cream, 5%
Description: Permethrin Cream 5%
Study: NCT00989703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
Study: NCT03178942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elimite™ Cream (permethrin) 5%
Description: Permethrin Cream 5%
Study: NCT04376632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pecan ADD
Description: Raw pecan halves without dietary substitution instructions

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pecan SUB
Description: Raw pecan halves with instructions to substitute pecans with isocaloric foods in the habitual diet
Study: NCT01429623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ladostigil hemitartrate
Description: 10mg ladostigil base administered once daily as hard gelatin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT01318902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.
Study: NCT03831555

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREP-C
Description: The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~1. Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~2. Information: knowledge about HCV treatment and one's own HCV disease status~3. Medication Adherence: current prescribed medications and adherence to them in the prior month~4. Self-efficacy: self-confidence about adhering to HCV treatment~5. Social Support and Stability: stability of financial, housing, and social support resources~6. Alcohol and substance use: alcohol and substance use behaviors and current treatment~7. Psychiatric Stability: current psychiatric status, previous and current treatment~8. Energy Level: sleep and fatigue~9. Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory.
Study: NCT03357705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar ridge preservation with synthetic bone
Description: after tooth extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar ridge preservation with bovine collagen
Description: after tooth extraction
Study: NCT01834651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
Study: NCT02141724

Intervention type: OTHER
Intervention: Positioning consultation
Description: Assessment of pain,bedsores and postural troubles
Study: NCT01096186

Intervention type: DRUG
Group type: OTHER
Intervention: IPX066 95 mg
Description: 23.75 - 95 mg CD-LD capsules

Intervention type: DRUG
Group type: OTHER
Intervention: IPX066 145 mg
Description: 36.25 - 145 mg CD-LD capsules

Intervention type: DRUG
Group type: OTHER
Intervention: IPX066 195 mg
Description: 48.75 - 195 mg CD-LD capsules

Intervention type: DRUG
Group type: OTHER
Intervention: IPX066 245 mg
Description: 61.25 - 245 mg CD-LD capsules
Study: NCT04759170

Intervention type: OTHER
Group type: OTHER
Intervention: Music therapy
Description: The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby

Intervention type: OTHER
Group type: OTHER
Intervention: Music therapy
Description: The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby

Intervention type: OTHER
Group type: OTHER
Intervention: Music therapy
Description: The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby

Intervention type: OTHER
Group type: OTHER
Intervention: Music therapy
Description: The effects of receptive music therapy on oral nutrition and the well-being of the Italian premature baby
Study: NCT03473301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of allogeneic umbilical cord blood
Description: Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of allogeneic umbilical cord blood
Description: Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of MSCs
Description: Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).
Study: NCT01810107

Intervention type: PROCEDURE
Intervention: Children Examined with the OCT Probe
Description: The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.

Intervention type: PROCEDURE
Intervention: Children Examined with the OCT Probe
Description: The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
Study: NCT01318902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets.
Study: NCT02846675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous SVF
Description: SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a Placebo treatment without SVF cells
Study: NCT01164501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets identical to BI 10773 low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical to BI 10773 high dose
Study: NCT02959892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine
Description: Amphetamine tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphetamine
Description: Amphetamine tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK -041
Description: TAK-041 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK -041
Description: TAK-041 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
Description: \[11C\]PHNO injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
Description: \[11C\]PHNO injection.
Study: NCT00794625

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral family counseling
Description: Weekly behavioral counseling with a therapist
Study: NCT04673695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixiana(D006)
Description: NOAC(Factor Xa inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixiana(D006)
Description: NOAC(Factor Xa inhibitor)
Study: NCT01164501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets identical to BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets identical to BI 10773 high dose
Study: NCT01235533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-3 polyunsaturated fatty acids
Description: Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: N-3 polyunsaturated fatty acids
Description: Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
Study: NCT01096667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertuglilflozin 1 or 5 mg
Description: Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
Study: NCT02185144

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
Study: NCT04673695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-344
Description: NOAC(Factor Xa inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-344
Description: NOAC(Factor Xa inhibitor)
Study: NCT02211742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
Study: NCT01096667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ertuglilflozin 1 or 5 mg
Description: Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ertuglilflozin 1 or 5 mg
Description: Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 1 mg
Description: Ertugliflozin tablet 1 mg once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Description: Ertugliflozin tablet 5 mg once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg
Description: Ertugliflozin tablet 25 mg once daily for 28 days
Study: NCT04109131

Intervention type: OTHER
Group type: OTHER
Intervention: Samples collection: Plasma
Description: At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)

Intervention type: OTHER
Group type: OTHER
Intervention: Samples collection: CSF
Description: Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice

Intervention type: OTHER
Group type: OTHER
Intervention: Samples collection: Non-CNS Metastatic Tumour Tissue
Description: Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI
Description: Part A:~* Brain MRI at inclusion is allowed within 45 days before enrolment~* Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)

Intervention type: OTHER
Group type: OTHER
Intervention: Samples collection: Serum
Description: At baseline~Part A:~* TNBC/ HER2+ BC: once a year~* NSCLC/SCLC: every 4 months~* Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis for cohorts 1-5.
Study: NCT02648542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compensatory auditory stimulation
Description: Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Low-current electrical brain stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Combined CAS and tDCS
Description: Combined auditory and electrical stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation
Study: NCT03939897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study: NCT02211742

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin
Description: euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
Study: NCT01115010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscope stiffening device
Description: Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned.
Study: NCT03939897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Given PO
Study: NCT01096667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ 12.5mg
Description: Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
Study: NCT01115010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscope stiffening device
Description: Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscope stiffening device
Description: Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned.
Study: NCT01260792

Intervention type: OTHER
Intervention: questionnaire
Description: The teachers or the professors complete questionnaires on the child on their behavior in classes

Intervention type: OTHER
Intervention: Questionnaire
Description: The parents complete a questionnaire on the behavior of their child and on their own behavior
Study: NCT03939897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study: NCT06274476

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: ridge splitting piezo surgery and implant placement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: implant placement
Description: ridge splitting piezo surgery and implant placement
Study: NCT01096667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to HCTZ
Description: Placebo to HCTZ 12.5 mg capsule once daily for 28 days
Study: NCT03939897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copanlisib Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging
Study: NCT01096667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to HCTZ
Description: Placebo to HCTZ 12.5 mg capsule once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to HCTZ
Description: Placebo to HCTZ 12.5 mg capsule once daily for 28 days
Study: NCT03939897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Imaging
Description: Undergo imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT01096667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to HCTZ
Description: Placebo to HCTZ 12.5 mg capsule once daily for 28 days
Study: NCT03939897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT01096667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ertuglilflozin 25 mg
Description: Placebo to ertuglilflozin tablet 25 mg once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ertuglilflozin 25 mg
Description: Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
Study: NCT03939897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT03569631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: 25 mg BPN14770 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules to mimic 25 mg BPN14770 capsules